CY1116247T1 - Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1 - Google Patents

Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Info

Publication number
CY1116247T1
CY1116247T1 CY20151100379T CY151100379T CY1116247T1 CY 1116247 T1 CY1116247 T1 CY 1116247T1 CY 20151100379 T CY20151100379 T CY 20151100379T CY 151100379 T CY151100379 T CY 151100379T CY 1116247 T1 CY1116247 T1 CY 1116247T1
Authority
CY
Cyprus
Prior art keywords
multiple myeloma
antibody
treatment methods
combination therapies
based combination
Prior art date
Application number
CY20151100379T
Other languages
English (en)
Inventor
Daniel Afar
Kenneth C Anderson
Yu-Tzu Tai
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116247(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of CY1116247T1 publication Critical patent/CY1116247T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Σύνθεση κατάλληλη για την θεραπεία του πολλαπλού μυελώματος σε ένα άτομο, που περιλαμβάνει μία θεραπευτικά αποτελεσματική ποσότητα HuLuc63, μία θεραπευτικά αποτελεσματική ποσότητα lenalidomide και/ ή bortezomib, και ένα φαρμακευτικά αποδεκτό φορέα, όπου η εν λόγω σύνθεση είναι ικανή να χορηγηθεί σε μία αγωγή μοναδικής ή πολλαπλής δόσης.
CY20151100379T 2006-08-07 2015-04-24 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1 CY1116247T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
EP07840746.7A EP2068874B1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
CY1116247T1 true CY1116247T1 (el) 2017-02-08

Family

ID=38831279

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20151100379T CY1116247T1 (el) 2006-08-07 2015-04-24 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY20161100817T CY1117992T1 (el) 2006-08-07 2016-08-18 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε huluc63 μαζι με bortezomib
CY2016037C CY2016037I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY2016038C CY2016038I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY2016036C CY2016036I2 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20161100817T CY1117992T1 (el) 2006-08-07 2016-08-18 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε huluc63 μαζι με bortezomib
CY2016037C CY2016037I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY2016038C CY2016038I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY2016036C CY2016036I2 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Country Status (24)

Country Link
US (4) US8632772B2 (el)
EP (5) EP2641600A1 (el)
JP (1) JP5340935B2 (el)
CN (1) CN101686971B (el)
AU (1) AU2007281684C1 (el)
BR (1) BRPI0716647A2 (el)
CA (1) CA2660356C (el)
CY (5) CY1116247T1 (el)
DK (2) DK2641601T3 (el)
ES (2) ES2535437T3 (el)
HK (1) HK1129853A1 (el)
HR (2) HRP20150449T1 (el)
HU (4) HUE029027T2 (el)
IL (2) IL196919A (el)
LT (4) LT2641601T (el)
LU (3) LU93276I2 (el)
MX (1) MX2009001441A (el)
NL (1) NL300840I2 (el)
NO (1) NO346835B1 (el)
NZ (1) NZ574978A (el)
PL (2) PL2641601T3 (el)
PT (2) PT2641601T (el)
SI (2) SI2641601T1 (el)
WO (1) WO2008019378A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2641601T3 (pl) 2006-08-07 2017-01-31 Abbvie Biotherapeutics Inc. Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na zastosowaniu HuLuc63 i bortezomibu
US7842293B2 (en) 2006-08-07 2010-11-30 Facet Biotech Corporation Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
WO2009149021A2 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
NZ589880A (en) 2008-06-16 2012-10-26 Immunogen Inc Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate
EP2349313A4 (en) * 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
WO2011030841A1 (ja) 2009-09-10 2011-03-17 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
CA2780998C (en) * 2009-11-24 2016-07-12 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
EP3071597B1 (en) * 2013-11-21 2020-07-29 F.Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
HUE054271T2 (hu) 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
PT3313528T (pt) 2015-06-29 2021-09-16 Bristol Myers Squibb Co Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
CN110382546B (zh) 2017-03-29 2024-08-09 新加坡科技研究局 抗寡糖抗体
CN111373246A (zh) * 2017-11-22 2020-07-03 希成生物医药 包括硼替佐米的聚合物纳米颗粒
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP4055392A1 (en) 2019-11-05 2022-09-14 Bristol-Myers Squibb Company M-protein assays and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
DE69633668T2 (de) 1995-05-25 2006-03-09 Shimon Slavin Allogene zelltherapie für krebs infolge allogener stammzellen transplantation
EP1505973B1 (en) * 2002-05-17 2010-03-03 Celgene Corporation Combinations for treating multiple myeloma
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20090175866A1 (en) * 2004-11-04 2009-07-09 Avner Yayon Treatment of b-cell malignancies
PL2641601T3 (pl) 2006-08-07 2017-01-31 Abbvie Biotherapeutics Inc. Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na zastosowaniu HuLuc63 i bortezomibu
US7842293B2 (en) * 2006-08-07 2010-11-30 Facet Biotech Corporation Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
EP2942057A1 (en) 2015-11-11
DK2068874T3 (da) 2015-04-27
EP2068874A1 (en) 2009-06-17
EP2641600A1 (en) 2013-09-25
HUE029027T2 (en) 2017-01-30
US20160137735A1 (en) 2016-05-19
CA2660356C (en) 2016-04-05
MX2009001441A (es) 2009-07-06
IL196919A (en) 2016-03-31
IL196919A0 (en) 2009-11-18
HUS1600045I1 (hu) 2016-12-28
HUS1600044I1 (hu) 2016-12-28
US8632772B2 (en) 2014-01-21
WO2008019378A1 (en) 2008-02-14
HRP20161284T1 (hr) 2016-12-16
LT2641601T (lt) 2016-10-10
EP2068874B1 (en) 2015-01-28
SI2068874T1 (sl) 2015-06-30
HUS1600043I1 (hu) 2016-12-28
EP2641601A1 (en) 2013-09-25
LTPA2016029I1 (lt) 2016-11-10
CY2016038I1 (el) 2017-07-12
LTPA2016030I1 (lt) 2016-11-10
SI2641601T1 (sl) 2016-11-30
CY2016036I1 (el) 2017-07-12
CY1117992T1 (el) 2017-05-17
CN101686971B (zh) 2013-09-11
CY2016036I2 (el) 2017-07-12
JP5340935B2 (ja) 2013-11-13
BRPI0716647A2 (pt) 2017-05-16
LU93277I2 (fr) 2016-12-27
NO20090968L (no) 2009-04-30
HRP20150449T1 (en) 2015-06-05
HK1129853A1 (en) 2009-12-11
NL300840I2 (el) 2017-01-03
JP2010500371A (ja) 2010-01-07
PT2068874E (pt) 2015-05-21
AU2007281684B2 (en) 2013-05-16
NZ574978A (en) 2012-08-31
CN101686971A (zh) 2010-03-31
DK2641601T3 (en) 2016-08-22
AU2007281684A1 (en) 2008-02-14
PL2641601T3 (pl) 2017-01-31
LU93275I2 (fr) 2016-12-27
IL243933A0 (en) 2016-04-21
EP3115049A1 (en) 2017-01-11
PL2068874T3 (pl) 2015-06-30
LTC2068874I2 (lt) 2018-11-12
US20080152646A1 (en) 2008-06-26
CA2660356A1 (en) 2008-02-14
EP2641601B8 (en) 2016-09-21
CY2016037I1 (el) 2017-07-12
EP2641601B1 (en) 2016-07-06
NO346835B1 (no) 2023-01-23
ES2589302T3 (es) 2016-11-11
US20140322201A1 (en) 2014-10-30
LTPA2016031I1 (lt) 2016-11-10
PT2641601T (pt) 2016-10-14
AU2007281684C1 (en) 2013-12-19
LU93276I2 (fr) 2016-12-27
ES2535437T3 (es) 2015-05-11
US20170342150A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CY1116247T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
CY1117154T1 (el) Συνθεσεις και μεθοδοι για τη διαγνωση και αγωγη του καρκινου
CY1122270T1 (el) Αντι-παραγοντα xi μονοκλωνικα αντισωματα και μεθοδοι χρησης αυτων
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
CY1111011T1 (el) Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1115046T1 (el) Καινουργια sirnas και μεθοδοι χρησης αυτων
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
EA200901211A1 (ru) Антигены белка с5 и их применение
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
CY1113975T1 (el) Παραγοντες για προληψη και θεραπεια διαταραχων που περιλαμβανουν διαφοροποιηση των υποδοχεων ryr
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
CY1110341T1 (el) Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CY1123792T1 (el) Συνθεσεις για καταστολη σχηματiσμου αναστολεων εναντι του παραγοντα viii σε ασθενεις με αιμορροφιλια α